APPROVAL PROCESS IS INITIATED
ARE READY & SECURED BY PATENTS
OUR NEW DRUG FOR THERAPY IS READY.
the health of those we serve.
- IT´S OUR DAILY CHALLENGE
It´s their goal realizing best medical solutions.
IS IN PROGRESS FOR APPROVAL
ARE READY & SECURED BY PATENTS
Pharmact
OUR MISSION
We focus on the most significant disease, where our new drug shows the effectiveness in the application of our therapy. Our goal is to improve your health.
.
Pharmact
INTERNATIONAL
We work worldwide with pharmaceutical whole-seller and distributions. We are pleased if you would like being part of our network.
.
.
Pharmact
NEW INGREDIENT
The development of the recombinant enzyme is patent-protected. It is used in the therapy of patients with arteriosclerosis and other diseases.
.
NEWS PRODUCTS
Screening for metabolic diseases on early stages
The effective therapy of diabetes mellitus and arteriosclerosis as well as their sequelae is one of the greatest medical challenges of our time. More…
NEW PROJECTS
New drug in process
Arteriosclerosis is a silent disease, which partly leads to calcifying with stiffening of vessel tissue. Pharmact has developed an optimal active drug by genetic engineering. The substance is has been brought in progress for the approval process as a pharmaceutical.
Interested in more?
Ask our partners!
DISTRIBUTION
EUROPE
Pharmact GmbH
Int´l Distribution
Headquarters
Phone: +49 621-1806178-0
E-Mail: sales@pharmact.de
USA
Pharmact Healthcare Inc.
Distribution
USA / CAN
Phone: +1 813 200 5884
E-Mail:
sales@pharmact.us
PARTNER
BBL Healthcare Solutions Ltd.
Distribution
Agency UK
Phone: +44 7848 844 048
E-Mail:
info@bblhealthcaresolutions.com